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Leukemia cutis associated with NPM1 mutation
A.Huen1, M.Luskin1, C.Stewart2, A.Perl1, M.Rosenbach1. 1University of
Pennsylvania, Philadelphia, PA, 2Lake Washington Dermatology, Kirkland, WA
Background: Leukemia cutis (LC) occurs in only a subset of patients with
leukemia and may be a sign of poor prognosis. It has association with monocytic
subtype (FAB type M4/M5) of acute myelogenous leukemia (AML) but other
factors predicting disease is lacking. Next-generation sequencing (NGS) of
hematologic malignancy-associated mutations has become available for evalua-
tion of leukemia patients. The aim of the study is to look for an association
between mutations and development of LC. Methods: Patients with non-M3
subtype leukemia were identified from our database in which NGS had been
performed on either leukemic blasts obtained during clinical care or from the
institutional tissue bank. Only pathogenic or disease-associated mutations were
included for analysis. Pathology data were reviewed for all patients and
independent review was performed for all indeterminate cases. The most
common molecular mutations were tested by logistic regression with adjustment
for FAB M4/M5. Results: 586 adult AML patients were identified with known
molecular genotype. In the initial analysis of 279 patients, molecular profile was
determined at initial diagnosis in 243 patients (88%) with other patients having
had prior therapy. Patients were at median age of 60 years (range 18-87) and
with 56% male. The majority of patients had intermediate cytogenetic risk (12%
favorable, 59% intermediate, 23% unfavorable, 6% unknown) and 41% of
patients had M4/M5 AML. The most common molecular mutations include
NPM1 (29%), DNMT3A (25%) and FLT3-ITD (23%). Leukemia cutis was found
in 26 patients (9%). NPM1 mutant status was present in 14 of 26 cases of
leukemia cutis (OR 3.17, 95% CI 1.40-7.20, p¼ 0.006). No association was
detected for LC and the presence of mutant FLT3-ITD (OR 1.27, p¼ 0.613),
mutant DNMT3A (OR 1.7, p¼0.224), or a mutation in any functional class of
AML mutations (all p-values NS). NPM1 status was found to be more common
in patients with M4/M5 AML (41% vs 23%, p¼ 0.003). The NPM1 association
with LC remained significant after adjustment for M4/M5 AML (OR 3.91,
p¼0.005). Among patients with M4/M5 AML, 10/12 (80%) patients with LC
were NPM1 mutant compared to 32/91 (35%) without LC suggesting that the
presence of mutated NPM1 was significantly associated with the development of
LC (OR 9.22, p¼0.006). Conclusion: Using NGS, we identified an association
between NPM1 mutation status and LC. Further investigation of this association
in a larger dataset is planned.
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Epidemiology and treatment of eosinophilic fasciitis: A retrospective
analysis from three tertiary care centers
N. Wright1, D. Mazori1, M. Patel1, J. Lin3, J. Merola1, A. Femia2, R. Vleugels1.
1Brigham and Women’s Hospital, Boston, MA, 2New York University Langone
Medical Center, New York, NY, 3Massachusetts General Hospital, Boston, MA
Background: Eosinophilic fasciitis (EF) is a rare connective tissue disease char-
acterized by edema and induration of the extremities that can result in joint
contractures and disability. Systemic corticosteroids (CS) remain the initial treat-
ment of choice; however, many patients require a prolonged treatment course and
no standard therapeutic protocol exists. Methods: Utilizing the Research Patient
Data Registry and 2 institutional electronic medical record systems containing over
5 million patient charts, we queried EF-related ICD-9 codes (728.89, 729.4, 728.9)
and used a natural language search of "fasciitis" or "disorder of muscle, ligament,
and fascia" to identify patients with EF at 3 large tertiary care centers over a 20-year
period. Data were extracted on demographics, disease presentation, treatment, and
clinical response. Results: Of the 1,626 fasciitis patients identified, 61 had EF (42
women, 19 men; mean age 56.8 years). Seventy percent (n¼ 43) had edema,
induration, a "groove sign," and/or pseudocellulite appearance of the upper and
lower extremities; 25% (n¼15) and 5% (n¼3) had findings only in the lower or
upper extremities, respectively. Thirty-four percent (n¼ 21) had concomitant
truncal plaque morphea, and 48% (n¼ 29) had joint contractures. When tested,
66% had peripheral eosinophilia and 16% had a monoclonal gammopathy.
Seventy-seven percent were misdiagnosed with diseases including systemic
sclerosis and hypereosinophilic syndrome, among other conditions. The mean
time from symptom onset to treatment was 10.4 months. Patients treated within 6
months of initial symptoms had a 60% complete response (CR) rate, compared
with 43% when treated after 6 months. Twenty-nine patients initially received CS
alone; 97% were responders, 31% with CR. Forty-one patients were treated with
combination therapy, most often with CS and methotrexate; 100% were
responders, 49% with CR. Conclusion: This retrospective review represents the
largest EF cohort to date. Patients were often misdiagnosed, resulting in delayed
treatment, invasive procedures, and inappropriate therapies. Complete response
occurred more often in patients treated within 6 months of symptom onset and in
those receiving combination therapy. Given the high rate of morbidity in EF, as
corroborated by this study, these results emphasize the importance of early
treatment and the role for combination therapy. Further investigation is needed
to determine an appropriate treatment algorithm for EF.
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The natural history of the cutaneous immune system in stem cell
transplantation and graft versus host disease
C. Stewart1,2, C. Cornejo2, R. Micheletti2, M. Rosenbach2, E. Kim2. 1Lake
Washington Dermatology, Kirkland, WA, 2University of Pennsylvania,
Philadelphia, PA
Graft versus host disease (GVHD) is a common and often debilitating
complication of allogeneic hematopoietic stem cell transplantation (aHSCT).
Though the skin is commonly affected, the natural history of host and donor
immune cells in the skin in aHSCT and GVHD has not been well described.
We prospectively studied the skin of seven patients receiving sex-mismatched
aHSCT. We biopsied their skin at specific time points: 1) prior to transplant, 2)
day fourteen post-transplant, and 3) engraftment. If GVHD developed, 4)
lesional and 5) non-lesional skin biopsies were performed. Using a combina-
tion of immunohistochemistry (CD1a, CD3, CD4, CD8, CD20 and CD56), and
fluorescent in situ hybridization (X and Y chromosomes), we investigated the
changing immune profile of the skin and evaluated for the presence of donor
cells at these different time points. Five of the seven patients developed GVHD.
Donor cells were consistently seen in lesional skin, as early as post-transplant
day 23. Donor cells were absent at all other time points, including in non-
lesional skin. In lesional samples, CD3/CD8 positive cells were predominant,
and CD4 staining was low and variable. CD3, CD4 and CD8 positive cells
were also seen in lower quantities in non-lesional samples. CD1a staining was
highly variable across all samples, and may have been impacted by
conditioning regimen. CD20 staining was negative in all samples, and scant
CD56 staining was observed in the lesional acute GVHD in two patients.
Further prospective studies of skin GVHD are needed to elaborate on these
results.
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Biochip immunofluorescence microscopy as a new diagnostic tool for
autoimmune blistering skin diseases in Australia
Y. Z. Chiang1, C. Y. Zhao2, W. Melbourne2, A. Wijayanti1, K. Tran1, J. Kim1,
K. Legaspi1, N. Ishii3, H. Koga3, E. Schmidt4, D. Zillikens4, T. Hashimoto3,
D. Murrell1. 1St George Hospital, Sydney, NSW, Australia, 2University of
New South Wales, Sydney, Australia, 3Kurume University, Kurume, Fukuoka,
Japan,4University of Luebeck, Luebeck, Germany
Introduction: Autoimmune blistering skin diseases are a group of disorders
characterised by autoantibodies targeting important structural proteins in the
skin that mediate cell-cell or cell-matrix adhesion. Recently, the Biochip mosaic-
based indirect immunofluorescence technique has been made available in
Australia to allow polyvalent immunofluorescence tests and provide antibody
profiles in a single incubation. Our aim is to determine the sensitivity and
specificity of the Biochip technique, using the enzyme-linked immunosorbent
assay (ELISA) as the gold standard control. Methods: Sera from patients with
provisional diagnoses of autoimmune blistering skin diseases were collected
prospectively and sent to the pathology laboratory for indirect immunofluores-
cence microscopy using the Biochip method and to Japan for ELISA. The Biochip
mosaic contained 6 test substrates which included monkey oesophagus, human
salt-split skin, bullous pemphigoid (BP) antigen 180, desmoglein (Dsg) 1, Dsg 3,
and BP230. The results were compared with each other. Results: So far, 29 results
from 24 patients were included: 9 had pemphigus vulgaris (PV), 2 had pemphigus
foliaceus (PF) and 13 had BP. The Biochip has good diagnostic sensitivities for PV
on cells transfected with Dsg 1 (100%) and Dsg 3 (90%). The specificities for Dsg
1 and Dsg 3 were 70% and 50% respectively. In patients with BP, the Biochip
also has a good diagnostic sensitivity (100%) and specificity (64%) for BP 230.
The sensitivity (67%) and specificity (57%) for BP 180 were lower than that for BP
230. Conclusion: The Biochip mosaic-based indirect immunofluorescence
technique presents a novel and faster way of diagnosing autoimmune blistering
skin diseases. Our preliminary results showed that the Biochip method has a high
diagnostic accuracy for PV and BP. 12 months. The remainder of lesions remain
in clinical remission. No long term sequelae were observed. Conclusion: This
study demonstrates that low-dose HDR brachytherapy provides excellent pallia-
tion for local control of acral CTCL lesions, offering homogenous, controlled
dosing to complex topographical sites. Minimal to no cutaneous toxicity was
observed. Overall, patients experienced improved cosmetic appearance and
functionality as well as sustained lesion recurrence free survival.
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Clinical features, etiologic associations, and treatment of palmoplantar
pustulosis: A retrospective review of the Mayo Clinic experience,
1996-2013
J. Olazagasti1,2, D. Wetter2. 1University of Puerto Rico, San Juan, Puerto Rico,
2Mayo Clinic, Rochester, Rochester, MN
Objective: Palmoplantar pustulosis (PPP) is a chronic disease with marked
impairment of quality of life. PPP is one of the cutaneous manifestations that
may occur in patients with SAPHO syndrome. Other autoimmune disorders
such as thyroid disease and gluten sensitivity have been linked to PPP, but
additional studies are necessary to clarify these associations. Treatment of PPP
is challenging and a therapeutic standard has yet to be defined. We sought to
further characterize clinical characteristics, etiologic associations, and treat-
ment of PPP. Methods: We conducted a retrospective review of patients with
PPP seen between 1996 and 2013. PPP was defined as recurrent, discrete 1-10
mm sterile pustules on the palmoplantar region. Patients in whom the body
surface area outside the palmoplantar region was45% were excluded as they
were considered to be affected by diffuse plaque psoriasis or generalized
pustular psoriasis with palmoplantar involvement. Results: A total of 119 cases
were included in the study. There were 95 female and 24 male patients. The
mean age at onset was 48.5 years. Four (3.4%) patients had a family history of
PPP and 23 (19.3%) patients had a family history of psoriasis. Twenty (16.8%)
patients had a personal history positive for minimal or mild psoriasis vulgaris (5
had pre-existing psoriasis, 9 presented with psoriasis at time of PPP diagnosis,
and 6 developed psoriasis after PPP diagnosis). Seventy-three (61.3%) of
patients were current smokers or had a previous history of smoking. In terms of
comorbidities, 7 patients (5.9%) had SAPHO syndrome, 7 (5.9%) had thyroid
disease, and 1 (0.8%) had gluten sensitivity. In all, 111 (93.3%) patients
received topical corticosteroids, 19 (16.0%) patients received acitretin, 22
(18.5%) received methotrexate, 39 (32.8%) received phototherapy, and 4
(3.4%) used TNF-a inhibitor therapy. Conclusions: More than half of patients in
this study did have a history of smoking, which is considered a precipitating or
aggravating factor for PPP. As reported in the literature, prevalence of minimal
or mild psoriasis vulgaris in patients with PPP is higher than in the general
population. Regarding autoimmune diseases, thyroid disease and gluten
sensitivity were found less frequently than previously reported. Treatment
regimens in our cohort varied greatly. Overall, about a third of patients in our
study required treatment with oral drugs and/or UV radiation in order to
control their disease.
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Granulomatous and neutrophilic dermatoses among patients with multi
organ disease
N. Lajevardi, A. Qureshi and L. Robinson. Bostom, Brown University,
Providence, RI
In this case series, we introduce a number of patients with multi organ disease
including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and uveitis
who presented with skin findings clinically and histologically consistent with
granulomatous and neutrophilic disease. Skin findings included bright red and
pink papules, annular plaques, and pustules on the scalp, trunk, and
extremities in varying degrees among the different patients. Some patients
were found to have only granulomatous or neutrophilic disease while others
were found to have an overlap of the two. Though neutrophilic dermatoses
such as Sweet’s syndrome and pyoderma gangrenosum are known to be
associated with inflammatory bowel disease and rheumatoid arthritis, our case
series illustrates the wide variety of granulomatous and neutrophilic skin
manifestations found in conjunction with systemic disease including the
musculoskeletal, gastrointestinal and ocular systems. Thus, we bring to
clinicians’ attention the spectrum of granulomatous and neutrophilic disease
among patients with multi organ disease. We also bring to light the possible
need to categorize these patients as part of a separate clinical entity altogether,
rather than describing their skin disease as separate from their systemic disease.
7
Hydralazine-induced vasculitis: A potentially delayed diagnosis in
critically ill patients
A. Keyes and J. Harp. Weill Cornell Medical College, New York, NY
Hydralazine induced vasculitis is a well-recognized entity; however, there are
limited case reports highlighting the potentially devastating outcomes. In
particular, pulmonary, renal and aerodigestive tract involvement can be life
threatening. We present two cases of hydralazine-induced vasculitis in which
prompt recognition and discontinuation of the medication, as well as initiation
of systemic corticosteroids, lead to recovery. These cases highlight a unique
presentation of mucosal and acral vesiculopustules in the critically ill patient.
Additionally, the importance of considering a long-standing medication
as the culprit of a drug induced vasculitis is emphasized. A 71-year old
woman with hypertension, diabetes and end stage renal disease on hemodia-
lysis presented to the emergency department for 2 days of odynophagia,
shortness of breath and a mucocutaneous eruption. Physical exam revealed
tense hemorrhagic vesiculopustules on the elbows, palms, fingers, lower legs
and toes, as well as ulcerations of the tongue and conjunctival injection. The
patient was intubated for airway protection and started on intravenous
dexamethasone for airway edema. An infectious work up was performed with
negative blood and sputum cultures. Tissue cultures of the skin, as well as
superficial bacterial cultures, viral cultures and DFA for herpes simplex virus
and varicella zoster virus were negative as well. Laboratory studies were
notable for an antinuclear antibody of 1:320, positive anti-histone antibody
and positive anti-neutrophil cytoplasmic antibodies. Skin biopsies obtained
from two locations demonstrated a necrotizing leukocytoclastic vasculitis with
foci of neutrophilic interface dermatitis and subepidermal bulla formation.
Infectious stains were negative. Home medications were reviewed with
concern for a drug-induced etiology. Hydralazine was discontinued and
systemic steroids were increased with resolution of the mucocutaneous
eruption. The treatment course was complicated by gastrointestinal bleeding
when steroids were tapered; an esophageal biopsy revealed a neutrophil rich
necrotizing process similar to the cutaneous biopsy and the bleeding resolved
with increased corticosteroid dose. The second patient is an 83-year-old man
with a history of coronary artery disease, ischemic cardiomyopathy and
chronic kidney disease who presented with worsening shortness of breath
and hypoxia. On day two of hospitalization he developed erythema of the right
arm thought to be gout and was treated with a trial of corticosteroids. For
worsening erythema, the development of vesiculopustules and leukocytosis,
corticosteroids were discontinued and he was started on broad-spectrum
antibiotics. Dermatology was consulted by the medical intensive care unit
on day eight of admission for worsening vesiculopustules on the right arm as
well as hemorrhagic bullae on the fingers, toes and oropharynx. Again, an
extensive infectious work up was performed with negative blood, sputum,
urine and tissue cultures. Superficial wound culture of the right arm showed
white blood cells only. Laboratory studies were notable for an anti-nuclear
antibody of 1:320, positive anti-histone antibody and positive anti-neutrophil
cytoplasmic antibodies. A biopsy showed a necrotizing thrombogenic vasculo-
pathy affecting the capillaries and venules of the deeper dermis and dermal
subcuticular interface. Infectious stains were negative. As the patient continued
to have worsening respiratory distress and altered mental status despite
broad-spectrum antibiotics, a drug-based etiology was considered. Review of
medications included hydralazine, which was discontinued on day seven of
admission. After completing a course of vancomycin and zosyn without
clinical recovery, the patient was started on methylprednisolone with gradual
improvement in respiratory and mental status. Our cases highlight the
importance of considering noninfectious etiologies in the differential diagnosis
of vesiculopustules and multiorgan system dysfunction in the critically ill
patient. Mucosal and acral involvement is characteristic features of
hydralazine-induced vasculitis; these findings may allow early recognition of
the diagnosis (1). It is important to consider longstanding medications as
possible culprits, as duration of treatment prior to the onset of hydralazine-
induced vasculitis has been reported as long as two years (2). In our
second patient, vesiculopustules developed during a complex hospitalization
making a home medication a less obvious cause. Hydralazine-induced
vasculitis is a potentially catastrophic diagnosis; early recognition, prompt
discontinuation of the medication and treatment with systemic corticosteroids
can be life-saving.
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